Un article de recherche de QUAMED

Dans un article publié dans le BMJ Global Health, qu'on peut retrouver dans le site web du journal (, nous avons évalué les systèmes d'assurance de qualité des distributeurs de médicaments, actifs en Afrique Sub-Saharienne. Lire la suite en anglais ….

Our findings  suggests that international distributors based in Europe perform, on average, better than those based in sub-Saharan Africa. However, some weaknesses are ubiquitous and concern the most critical processes, such as the initial selection of the products and the ongoing reassessment of their quality. This is due to several different factors: weak regulatory oversight, insufficient human/financial resources, weak negotiating power, limited judicial autonomy and/or lack of institutional commitment to quality.

Even if based on a small, convenient sample of distributors, these  findings suggest that pharmaceutical distributors active in sub-Saharan Africa generally do not apply stringent criteria for selecting products and suppliers. Therefore, product quality is not consistently assured but depends on the requirements of purchasers.

While long-term solutions are awaited, we strongly suggest that collaboration and transparent exchange of information between regulators from the North and the South should be pursued; and that the WHO MQAS guideline should be used by all concerned stakeholders as an evaluation and training tool to upgrade the current standards of practice of pharmaceutical distributors active in sub-Saharan Africa.

Ref: Nebot Giralt A, Schiavetti B, Meessen B, et al. Quality assurance of medicines supplied to low income and middle-income countries: poor products in shiny boxes?. BMJ Global Health 2017;2:e000172. doi:10.1136/bmjgh-2016-0001